WallStSmart

Merck & Company Inc (MRK)vsPerrigo Company PLC (PRGO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1474% more annual revenue ($65.77B vs $4.18B). MRK leads profitability with a 13.6% profit margin vs -43.5%. PRGO appears more attractively valued with a PEG of 1.14. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

PRGO

Hold

45

out of 100

Grade: D+

Growth: 2.0Profit: 3.0Value: 7.0Quality: 4.5
Piotroski: 3/9Altman Z: 0.02
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued
PRGOUndervalued (+75.4%)

Margin of Safety

+75.4%

Fair Value

$59.32

Current Price

$10.83

$48.49 discount

UndervaluedFair: $59.32Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

PRGO1 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PRGO4 concerns · Avg: 3.0/10
Market CapQuality
$1.53B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.5%3/10

Operating margin of 3.5%

Debt/EquityHealth
1.523/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : PRGO

The strongest argument for PRGO centers on Price/Book. PEG of 1.14 suggests the stock is reasonably priced for its growth.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : PRGO

The primary concerns for PRGO are Market Cap, Operating Margin, Debt/Equity. Debt-to-equity of 1.52 is elevated, increasing financial risk.

Key Dynamics to Monitor

MRK profiles as a value stock while PRGO is a turnaround play — different risk/reward profiles.

PRGO carries more volatility with a beta of 0.54 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 45/100). PRGO offers better value entry with a 75.4% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Perrigo Company PLC

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Perrigo Company plc is an American Irish registered manufacturer of private label over-the-counter pharmaceuticals.

Visit Website →

Want to dig deeper into these stocks?